ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
vTv Therapeutics Inc

vTv Therapeutics Inc (VTVT)

21.72
-1.45
( -6.26% )
Actualizado: 10:11:32

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Estadísticas y detalles clave

Último Precio
21.72
Postura de Compra
22.30
Postura de Venta
23.00
Volume Operado de la Acción
10,792
20.88 Rango del Día 23.20
12.1201 Rango de 52 semanas 29.19
Capitalización de Mercado [m]
Precio Anterior
23.1699
Precio de Apertura
23.20
Última hora de negociación
10:11:34
Volumen financiero
US$ 237,983
Precio Promedio Ponderado
22.0518
Volumen promedio (3 m)
23,506
Acciones en circulación
3,189,606
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-3.81
Beneficio por acción (BPA)
-5.79
turnover
1.02M
Beneficio neto
-18.46M

Acerca de vTv Therapeutics Inc

vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (... vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sede
Wilmington, Delaware, USA
Fundado
-
vTv Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VTVT. The last closing price for vTv Therapeutics was US$23.17. Over the last year, vTv Therapeutics shares have traded in a share price range of US$ 12.1201 to US$ 29.19.

vTv Therapeutics currently has 3,189,606 shares in issue. The market capitalisation of vTv Therapeutics is US$73.90 million. vTv Therapeutics has a price to earnings ratio (PE ratio) of -3.81.

VTVT Últimas noticias

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
12.0810.590631364619.6423.218.89641021.29089194CS
44.6827.464788732417.0423.214.631061917.53993297CS
126.7244.81526.9914.52692350619.94827552CS
267.4752.421052631614.2526.9912.622435117.33578052CS
52-5.18-19.256505576226.929.1912.12012276317.2888561CS
156-6.58-23.250883392228.3567.3814779828.63245578CS
260-63.88-74.626168224385.6205.27.3885584998.75081022CS

VTVT - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de vTv Therapeutics?
El precio actual de las acciones de vTv Therapeutics es US$ 21.72
¿Cuántas acciones de vTv Therapeutics están en circulación?
vTv Therapeutics tiene 3,189,606 acciones en circulación
¿Cuál es la capitalización de mercado de vTv Therapeutics?
La capitalización de mercado de vTv Therapeutics es USD 73.9M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de vTv Therapeutics?
vTv Therapeutics ha negociado en un rango de US$ 12.1201 a US$ 29.19 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de vTv Therapeutics?
El ratio precio/beneficio de vTv Therapeutics es -3.81
¿Cuál es el ratio de efectivo a ventas de vTv Therapeutics?
El ratio de efectivo a ventas de vTv Therapeutics es 69.26
¿Cuál es la moneda de reporte de vTv Therapeutics?
vTv Therapeutics presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de vTv Therapeutics?
El último ingresos anual de vTv Therapeutics es USD 1.02M
¿Cuál es el último beneficio anual de vTv Therapeutics?
El último beneficio anual de vTv Therapeutics es USD -18.46M
¿Cuál es la dirección registrada de vTv Therapeutics?
La dirección registrada de vTv Therapeutics es 251 LITTLE FALLS DRIVE, OAKS PKWY, WILMINGTON, DELAWARE, 19808
¿Cuál es la dirección del sitio web de vTv Therapeutics?
La dirección del sitio web de vTv Therapeutics es vtvtherapeutics.com
¿En qué sector industrial opera vTv Therapeutics?
vTv Therapeutics opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
WWWW International Inc
US$ 0.868
(109.92%)
313.64M
LGMKLogicMark Inc
US$ 0.021
(62.79%)
2.26B
DMNDamon Inc
US$ 0.0059
(55.26%)
2.17B
OMHOhmyhome Ltd
US$ 3.02
(48.77%)
63.05M
WLDSWearable Devices Ltd
US$ 1.595
(32.92%)
39.39M
IXHLIncannex Healthcare Ltd
US$ 0.1407
(-76.93%)
12.16M
PTPIPetros Pharmaceuticals Inc
US$ 0.0202
(-65.11%)
169.84M
ZYBTZhengye Biotechnology Holding Ltd
US$ 6.44
(-54.49%)
512.05k
MWYNMarwynn Holdings Inc
US$ 2.72
(-33.17%)
1.62M
NEONeoGenomics Inc
US$ 7.43
(-25.48%)
2.11M
LGMKLogicMark Inc
US$ 0.021
(62.79%)
2.26B
DMNDamon Inc
US$ 0.0059
(55.26%)
2.17B
WWWW International Inc
US$ 0.868
(109.92%)
313.64M
BONBon Natural Life Ltd
US$ 0.0765
(17.69%)
217.35M
GNLNGreenlane Holdings Inc
US$ 0.0122
(1.67%)
207.63M

VTVT Discussion

Ver más
dinogreeves dinogreeves 1 mes hace
Baker Brothers is on this too, wait till you see $DRUG run fairly soon. Probably as high as $MDGL
👍️0
dinogreeves dinogreeves 1 mes hace
nice cash in the coffers and fairly nice institutional holders.
👍️0
dinogreeves dinogreeves 1 mes hace
50 dollars coming soon, very soon.
👍️0
Awl416 Awl416 1 año hace
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
👍️0
dennisv dennisv 1 año hace
Cowboys2275: You Are Really A Special Cowboy!
https://stocktwits.com/cowboys2275/message/558967191
👍️0
dennisv dennisv 1 año hace
There will be More interest in VTVT!
👍️0
dennisv dennisv 1 año hace
https://zolmax.com/investing/vtv-therapeutics-inc-nasdaqvtvt-sees-large-increase-in-short-interest/9990102.html
👍️0
dennisv dennisv 1 año hace
American Bulls: Buy Signal!
https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=VTVT
👍️0
Monksdream Monksdream 2 años hace
VTVT new 52 week low
👍️0
AJ Freely AJ Freely 2 años hace
$VTVT- 👆Up 16% Pre-Market/Current Price $0.78
👉Cantex Pharmaceuticals Publishes Article in npj Breast Cancer Highlighting Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer
👉Originally developed for Alzheimer's disease by vTv
👍️0
81vette 81vette 2 años hace
2 week long runs in past on news and this is awesome news
👍️0
81vette 81vette 2 años hace
Zero borrow and not optionable,low float target $4,insider trans up 145%
👍️0
81vette 81vette 2 años hace
Zero borrow and not optionable,low float target $4,insider trans up 145%
👍️0
TheFinalCD TheFinalCD 2 años hace
https://finviz.com/quote.ashx?t=VTVT&ty=c&ta=1&p=d
👍️0
N-13 N-13 3 años hace
I guess I spoke too soon.
👍️0
N-13 N-13 3 años hace
Wow, we closed over 70 cents!
👍️0
Investor2014 Investor2014 3 años hace
Because the company keeps spending and raising money without achieving anything.
👍️0
N-13 N-13 3 años hace
Why, so difficult to get over 70 cents?
👍️0
N-13 N-13 3 años hace
What's with the knuckleheads that are trading pre and post market?
👍️0
surf1944 surf1944 3 años hace
https://stockcharts.com/h-sc/ui?s=VTVT&p=D&yr=0&mn=6&dy=0&id=p38090673899

Filled open gap .62 this morning!
👍️0
Golden Cross Golden Cross 3 años hace
$VTVT Huge Vol Alert
👍️0
cjstocksup cjstocksup 3 años hace
@bc9114 The $12.5m ( 5,193,187 shares) in shares distribution to G42 Healthcare were dilutive shares resulting in a increase in total outstanding shares from 90,036,637 to 95,229,824. The float will remain at 30,346,158 because G42 Healthcare will become an affiliate in the next 30 days.

“Lock-Up Period” means the period from the date of this Agreement until December 31, 2024 (or, if earlier, the date of receipt of FDA Approval). I love this Lock-Up Period : ) which is located on page 5.

These particular shares are classified as Unregistered Securities that orginated from the LPC Agreement which had $35.9 remaining available as of March 31st, 2022 & as a result of the G42 Healthcare Partnership the remaining availability under the LPC Agreement is now at $23.4m.

Common Stock Purchase Agreement: (Unregistered Securities)
sec.gov/Archives/edgar/data...

In the next 30 days Vtv's board will increase to 6 & will add
Dr. Fahed Al Marzooqi the COO of G42 Healthcare.
👍️0
cjstocksup cjstocksup 3 años hace
Read today's news it already happened at $2.41 per share.
👍️0
Pt3 Pt3 3 años hace
What a good talk ....when is offering
👍️0
cjstocksup cjstocksup 3 años hace
We churned over the float but those who bought premarket up to $1.18 panic sold on the red open and the rest of the day others panic sold red down. Bottom line the 25-million-dollar investment is huge. We should be up a couple dollars. I am patient. We have more news on the way.
VTVT: This could run-up nicely today, behind substantive news of late and a $5.00 price prediction.
👍️0
Pt3 Pt3 3 años hace
What going on here bulls ....just bought 5000 shares need info
👍️0
crudeoil24 crudeoil24 3 años hace
Yes, I read that filing earlier!
👍️0
cjstocksup cjstocksup 3 años hace
New SEC Filing: 8-K Material Agrmt - vTv Therapeutics Inc. (0001641489) May 31


Item 1.01Entry into a Material Definitive Agreement Common Stock Purchase Agreement On May 31, 2022, vTv Therapeutics Inc. (the "Company") and G42 Investments AI Holding RSC Ltd, a private limited company ("G42 Investments"), entered into a common stock purchase agreement (the "Purchase Agreement"), pursuant to which the Company agreed to sell to G42 Investments 10,386,274 shares of the Company's Class A common stock, par value $0.01 per share (the "Common Stock" and such shares, the "Closing Shares") at a price per share of approximately $2.41, for an aggregate purchase price of $25,000,000, which was paid (i) $12,500,000 in cash at the closing of the transaction and (ii) $12,500,000 in the (...)

marketnewswire.live/index.p...
👍️0
Awl416 Awl416 3 años hace
News
👍️0
crudeoil24 crudeoil24 3 años hace
vTv Therapeutics Announces Entry Into Agreements That Include $25M Investment By G42 Investments AI Holding RSC
6:56 am ET June 1, 2022 (Benzinga) Print
vTv Therapeutics Inc. (NASDAQ:VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC Ltd ("G42 Investments"). Under the terms of the agreements, G42 Investments acquired 10,386,274 shares of Class A Common Stock of vTv at an issue price of $2.407 per share, with $12.5 million paid in cash at closing, and the remaining amount of $12.5 million payable on May 31, 2023. The agreements also provide for the potential issuance of $30 million in additional shares of Class A Common Stock to G42 Investments (or cash in lieu of such issuance at the option of G42 Investments) if the United States Food and Drug Administration (the "FDA") approves the marketing and sale of a pharmaceutical product containing TTP399, a liver selective glucokinase activator, as the active ingredient for treatment of type 1 diabetes in the United States. The agreements set forth the terms under which vTv and an affiliate of G42 plan to collaborate on clinical trials for pharmaceutical products that contain TTP399, including G42's affiliate funding a portion of the Phase 3 clinical trials for TTP399, and vTv granting G42's affiliate an exclusive license to develop and commercialize pharmaceutical products containing TTP399 in certain territories outside of the United States and the European Union.

"We have focused substantial energy and resources on TTP399 since obtaining Breakthrough Therapy designation from the FDA in April 2021 and are thrilled to welcome a partner to work with us to accelerate the development and potential approval and commercialization of this treatment. G42 Healthcare brings a unique combination of strong commitment to the development of new impactful drugs and treatments, as demonstrated by their success and their leadership on COVID-19 testing and other product and service offerings in the healthcare spectrum, and substantial resources, making them an ideal partner for this program. This investment into vTv will fund a substantial portion of our Phase 3 clinical trials for TTP399 in the United States and the collaboration with G42 will fund certain of the Phase 3 clinical trials that will be conducted in other territories. We are excited to partner with the G42 Healthcare team as we launch our Phase 3 clinical trials and work together towards approval and commercialization of this treatment for type 1 diabetes," said Rich Nelson, Interim Chief Executive Officer of vTv.

Dr. Fahed Al Marzooqi, the Chief Operating Officer of G42 Healthcare, noted that "We have a deep commitment to collaborating with international organizations to share our knowledge and expertise in the consumer and clinical health spectrum and we look forward to working together with vTv to further develop and commercialize this important treatment. As we move ahead, we will continue to join forces with the world's best to innovate and invest in science and create the next wave of medicines to future-proof the health of nations."

A more detailed description of the agreements is set forth in vTv's Current Report on Form 8-K filed with the SEC. The Stock Purchase Agreement is attached to the Current Report on Form 8-K and the Collaboration and License Agreement will be filed with vTv's Quarterly Report on Form 10-Q for the second quarter.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor will there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
👍️0
Investor2014 Investor2014 3 años hace
Or drop big
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 3 años hace
$VTVT
https://twitter.com/quabbinr/status/1495541185615695880?s=21
👍️0
Just-Keep-Trying Just-Keep-Trying 3 años hace
VTVT: This could run-up nicely today, behind substantive news of late and a $5.00 price prediction.
👍️0
Tom turtles Tom turtles 4 años hace
Really not till the start of 2022....but you never know when they'll drop a biggie
👍️0
murocman murocman 4 años hace
I am surprised this has not gotten more traction and visibility after releasing good trial data.

The Type 1 diabetes market is huge.

Any catalysts in the near term to help out?

Murocman
👍️0
Tom turtles Tom turtles 4 años hace
Too cheap to ignore here !
👍️0
Tom turtles Tom turtles 4 años hace
DWAC.....craziness
👍️0
murocman murocman 4 años hace
Likely because they are woefully behind on their financial filings.

Murocman
👍️0
Tom turtles Tom turtles 4 años hace
Well look at ADMP......they get FDA approval and the stock sells off......ya never know. GL with your trades...
👍️0
Investor2014 Investor2014 4 años hace
P2 trials planned to initiate in 2022. I can’t see those increasing $VTVT as just adding more cost and likely more dilution.

The price of $VTVT going up is linked to the success of those trials.

I might invest at some point before readout if I think the risk/reward looks attractive. Need to see P2 trial protocols first.
👍️0
Tom turtles Tom turtles 4 años hace
Just need it to get past $3 over the next year. Think that's very doable. ITRM and ADMP couple others I'm watching.
👍️0
Tom turtles Tom turtles 4 años hace
Most of his shares were bought above $4. He recently bought 635,000 @ $1.60. I'm closing in on 100,000 shares. Hope I didn't make a mistake here.... Their trials haven't been very successful lately , and recently raised the O/S to 200M shares, which is still very low for a buck stock. ~ You have any other pharm plays that are ripe ? TIA.....
👍️0
Investor2014 Investor2014 4 años hace
Perelman has years ago signed an agreement with vTv funding them on demand by buying the shares they issue.

Insider buying on that basis doesn’t tell you very much other than perhaps Perelman may be a sucker holding a big bag.
👍️0
Tom turtles Tom turtles 4 años hace
It seems he owns about 80% of the company. Not sure how many shares he owns....couldn't find that number on insider trades...
👍️0
Tom turtles Tom turtles 4 años hace
You like this thing Invest2014 ? Right now looks bad.....but 2022 is gonna be huge. Why not accum now...and put in a drawer for a year. No doubt this will bust $5 next year. Been picking up all these $1.40s..New CEO.....inside buying ....lots of things going on here. Huge pipeline...Not just one and done drug. Picking up this and SYN for a long hold.
👍️0
Investor2014 Investor2014 4 años hace
It seems you can have most of the $VTVT that Perelman doesn’t own.
👍️0
Tom turtles Tom turtles 4 años hace
Almost filled up.
👍️0
Tom turtles Tom turtles 4 años hace
Bye buy bye buy
👍️0
Tom turtles Tom turtles 4 años hace
What a turd
👍️0
Tom turtles Tom turtles 4 años hace
I'll be able to buy that new Range Rover I've been looking at.....with cash !
👍️0

Su Consulta Reciente

Delayed Upgrade Clock